Views & Analysis ‘No going back’ for clinical trials after COVID Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result.
News Sources quash rumours of an AZ/BMS mega-merger A media report suggests there is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
